Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma

(2012) Satoru Hagiwara et al.   HEPATOLOGY RESEARCH

CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling

(2011) Kwan Ho Tang et al.   HEPATOLOGY

Signaling Pathways Governing Tumor Angiogenesis

(2011) Toshiharu Sakurai et al.   ONCOLOGY

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

(2010) S Whittaker et al.   ONCOGENE

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

(2009) Pippa Newell et al.   JOURNAL OF HEPATOLOGY

Hepatocyte Necrosis Induced by Oxidative Stress and IL-1α Release Mediate Carcinogen-Induced Compensatory Proliferation and Liver Tumorigenesis

(2008) Toshiharu Sakurai et al.   CANCER CELL

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation

(2008) Lijian Hui et al.   JOURNAL OF CLINICAL INVESTIGATION

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE